Mario E. Lacouture Discusses Adverse Effects of Targeted Therapies
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses some of the adverse effects of newly approved targeted therapies.
Mario E. Lacouture on the Psychosocial Impact of Dermatologic AEs
Mario E. Lacouture, MD, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
Dr. Lacouture on Preventing and Managing Melanoma Toxicities
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer, discusses how nurses can help prevent and manage skin toxicities associated with melanoma treatment.
Following Reconstruction, Patients With Early Breast Cancer May Safely Opt For a Shorter Course of Radiation Therapy
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
